Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

(PLXP)

(PLXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,282
  • Shares Outstanding, K 29,138
  • Annual Sales, $ 8,210 K
  • Annual Income, $ -46,130 K
  • 60-Month Beta 3.79
  • Price/Sales 0.53
  • Price/Cash Flow N/A
  • Price/Book 0.25
Trade PLXP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.55
  • Most Recent Earnings $-0.37 on 11/10/22
  • Latest Earnings Date 05/12/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +136,949.32%

Price Performance

See More
Period Period Low Period High Performance

Most Recent Stories

More News
PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PLXP : 0.0207 (unch)
BRBR : 58.80 (-0.99%)
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

MTEM : 2.36 (+3.06%)
PLXP : 0.0207 (unch)
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 9.53% and 0.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

JAZZ : 120.51 (+2.19%)
PLXP : 0.0207 (unch)
Baudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue Estimates

Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BXRX : 0.0218 (+7.39%)
PLXP : 0.0207 (unch)
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update

SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform...

PLXP : 0.0207 (unch)
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events...

PLXP : 0.0207 (unch)
PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PLXP : 0.0207 (unch)
PTE : 0.2410 (-0.82%)
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update

BUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth...

PLXP : 0.0207 (unch)
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update

SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform...

PLXP : 0.0207 (unch)
Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates

Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for...

PLXP : 0.0207 (unch)
MDWD : 15.10 (-2.96%)

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 0.0207
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.0418
Fibonacci 61.8% 0.0335
Fibonacci 50% 0.0310
Fibonacci 38.2% 0.0285
Last Price 0.0207
52-Week Low 0.0202

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar